Phosphate: An Anion Controlling Metabolic Functions.

Chronic obstructive pulmonary disease (COPD) is a progressive, heterogeneous respiratory disorder characterized by airflow limitation, persistent symptoms, and recurrent exacerbations []. It is a leading cause of morbidity and mortality worldwide and imposes a substantial burden on healthcare systems and society []. Despite advances in pharmacological and non-pharmacological interventions, optimal management of COPD remains a challenge, particularly in patients with persistent symptoms and frequent exacerbations []. Inhaled pharmacotherapy forms the cornerstone of COPD management. Current guidelines recommend long-acting bronchodilators, including long-acting muscarinic antagonists (LAMAs) and long-acting β₂-agonists (LABAs), either alone or in combination, as first-line therapy for symptomatic patients. Inhaled corticosteroids (ICS) are often added in combination with LABA and/or LAMA for patients with recurrent exacerbations, especially those with elevated blood eosinophil counts []. These therapeutic strategies have been refined through pivotal clinical trials, yet the comparative effectiveness and safety of dual versus triple inhaled therapy remain subjects of ongoing debate. Triple therapy (ICS/LAMA/LABA) is hypothesized to provide additive benefits by targeting multiple pathophysiological pathways, potentially improving lung function, reducing exacerbations, and enhancing health-related quality of life. Large randomized controlled trials (RCTs), such as the IMPACT and ETHOS studies [, ], have reported modest reductions in exacerbation rates with triple therapy compared with dual therapy, but also highlighted an increased risk of pneumonia, particularly with fluticasone-containing regimens. Dual therapies, particularly combinations such as fluticasone furoate/vilanterol (FF/VI) and budesonide/formoterol (BUD/FORM), remain widely prescribed and are often sufficient for many patients [].